Cytek Biosciences (CTKB) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.09
- EPS estimate
- −$0.09
- EPS surprise
- +3.54%
- Revenue surprise
- +1.76%
- Revenue
- $48.1M
- Revenue estimate
- $47.3M
- Reported
- Aug 5, 2026
Cytek Biosciences reported Q2 2026 results on August 5, 2026, posting a loss of $0.09 per share. That matched the rounded $0.09 loss estimate, a 3.54% beat on the table's surprise figure. Revenue of $48.1 million topped the $47.3 million consensus by 1.76%. Compared with Q2 2025, revenue grew about 5% from $45.6 million, while the loss widened from $0.04 per share.
Cytek has moved from small profits into losses. Annual EPS was $0.14 in 2022, $0.09 in 2023 and $0.14 in 2024, then a loss of $0.47 in 2025. Q4 2025's loss of $0.34 per share is the largest in the table, and Q4 2024's $0.12 profit is the highest. Revenue grew from $164.1 million in 2022 to $193.4 million in 2023, then flattened at $200.5 million in 2024 and $201.5 million in 2025. The first half of 2026 shows a loss of $0.24 per share, against $0.13 a year earlier, on revenue about 6% higher.
Q3 results arrived between November 5 and November 9 in each of the past five years. That points to early November 2026, when the report will show whether revenue growth continues and how the result compares with break-even in Q3 2025.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | −$0.09 | −$0.09 | +3.54% | $48.1M | SEC |
| Q1 2026 | May 7, 2026 | −$0.09 | −$0.15 | −62.16% | $44.1M | SEC |
| Q4 2025 | Feb 26, 2026 | −$0.02 | −$0.34 | −1600.00% | $62.1M | SEC |
| Q3 2025 | Nov 5, 2025 | −$0.03 | $0.00 | +114.00% | $52.3M | SEC |
| Q2 2025 | Aug 6, 2025 | −$0.05 | −$0.04 | +16.67% | $45.6M | SEC |
| Q1 2025 | May 8, 2025 | −$0.03 | −$0.09 | −172.73% | $41.5M | SEC |
| Q4 2024 | Feb 27, 2025 | $0.10 | $0.12 | +17.74% | $57.5M | SEC |
| Q3 2024 | Nov 5, 2024 | $0.01 | $0.06 | +448.70% | $51.5M | SEC |
| Q2 2024 | Aug 6, 2024 | −$0.00 | −$0.03 | −782.76% | $46.6M | SEC |
| Q1 2024 | May 8, 2024 | −$0.03 | −$0.01 | +72.40% | $44.9M | SEC |
| Q4 2023 | Mar 1, 2024 | $0.03 | $0.09 | +200.00% | $58.6M | SEC |
| Q3 2023 | Nov 7, 2023 | $0.02 | −$0.01 | −135.00% | $48.0M | SEC |
| Q2 2023 | Aug 8, 2023 | $0.01 | $0.01 | +15.00% | $49.7M | SEC |
| Q1 2023 | May 9, 2023 | $0.02 | $0.00 | −100.00% | $37.1M | SEC |
| Q4 2022 | Feb 28, 2023 | $0.04 | $0.06 | +41.18% | $48.3M | SEC |
| Q3 2022 | Nov 9, 2022 | $0.01 | $0.04 | +220.00% | $40.5M | SEC |
| Q2 2022 | Aug 10, 2022 | $0.01 | $0.03 | +140.00% | $40.2M | SEC |
| Q1 2022 | May 11, 2022 | −$0.01 | $0.01 | +200.00% | $35.1M | SEC |
| Q4 2021 | Feb 23, 2022 | $0.03 | $0.00 | −100.00% | $38.9M | SEC |
| Q3 2021 | Nov 8, 2021 | $0.02 | $0.02 | −14.16% | $34.4M | SEC |
Quarterly revenue
Frequently asked questions
When did Cytek Biosciences (CTKB) last report earnings?
Cytek Biosciences last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did CTKB beat earnings estimates?
Yes. Cytek Biosciences reported EPS of −$0.09 for Q2 2026 against a −$0.09 estimate — a 3.54% beat.
How much revenue did CTKB report last quarter?
Cytek Biosciences reported $48.1M in revenue for Q2 2026, against a consensus estimate of $47.3M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.